Danish biotechnology company NeuroSearch A/S (CPH:NEUR) confirmed on Thursday that it is in discussions with regard to the potential sale of its rights to Pridopidine for a small seven figure amount in DKK.
This is with reference to the article in MedWatch on 19 April 2018 relating to Teva giving up the development of the investigational medicinal product, Pridopidine.
NeuroSearch added that it is still investigating the potential sale of the company, but there is no certainty that these investigations will result in such a sale.
NeuroSearch will provide further information if and when required to do so.
Neurosearch specialises in pharmaceuticals for treating diseases and disorders affecting the central nervous system.
Hikma announces Health Canada approval of KLOXXADO Nasal Spray for opioid overdose treatment
Plus Therapeutics secures FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda
Latigo Biotherapeutics' LTG-001 receives US FDA Fast Track designation
GenSight Biologics reports positive five-year resultsfor LUMEVOQ gene therapy
Bain Capital to acquire Mitsubishi Tanabe Pharma in USD3.3bn deal
Innovent and ASK Pharm's limertinib NDA receives Chinese regulatory approval
Anavex reports positive long-term data for blarcamesine in early Alzheimer's disease
Johnson & Johnson agrees acquisition of Intra-Cellular Therapies Inc
Neuraxpharm acquires Provigil and Nuvigil to expand CNS portfolio
Nuvation Bio secures NMPA approval for taletrectinib in China
JCR Pharmaceuticals and Modalis Therapeutics advance to next phase of joint gene therapy research
PTC Therapeutics submits vatiquinone NDA to US FDA
Mitsubishi Tanabe Pharma forms research collaboration with Dewpoint Therapeutics
IXICO signs commercial agreement with PETNET Solutions to enhance neuroimaging capabilities